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Biological and empirical evidence suggests that rare variants account for a large proportion of the genetic contributions to complex
human diseases. Recent technological advances in high-throughput sequencing platforms have made it possible for researchers to
generate comprehensive information on rare variants in large samples. We provide a general framework for association testing with
rare variants by combining mutation information across multiple variant sites within a gene and relating the enriched genetic informa-
tion to disease phenotypes through appropriate regression models. Our framework covers all major study designs (i.e., case-control,
cross-sectional, cohort and family studies) and all common phenotypes (e.g., binary, quantitative, and age at onset), and it allows arbi-
trary covariates (e.g., environmental factors and ancestry variables). We derive theoretically optimal procedures for combining rare
mutations and construct suitable test statistics for various biological scenarios. The allele-frequency threshold can be fixed or variable.
The effects of the combined raremutations on the phenotype can be in the same direction or different directions. The proposedmethods
are statistically more powerful and computationally more efficient than existing ones. An application to a deep-resequencing study of
drug targets led to a discovery of rare variants associated with total cholesterol. The relevant software is freely available.Introduction
Genome-wide association studies (GWAS) with tagSNPs
have successfully identified common SNPs with small to
modest effects for virtually every complex human disease.
Technological advances in high-throughput sequencing
platforms have made it possible for researchers to extend
association studies to rare variants in targeted exons and
soon in the entire genome. Rare variants tend to be func-
tional alleles and have stronger effects on complex diseases
than common variants.1,2 Indeed, deep-resequencing
studies of candidate genes have already demonstrated the
influence of rare variants on several complex traits.3–5
Association testing with a single rare variant has limited
power because only a small percentage of study subjects
carry a rare mutation and there are a large number of tests
to be adjusted for. Collapsing or grouping methods, which
combine information across multiple variant sites within
a gene, can enrich association signals and reduce the
penalty of multiple testing. The simplest collapsing
method is the burden test, which is based on the number
of rare mutations each subject carries in a gene.6,7 A second
approach is the weighted sum statistic of Madsen and
Browning,8 which weights each mutation according to
its frequency in the unaffected subjects and permutes the
disease status to assess the significance of a Wilcoxon-
type test statistic. A third approach is the variable-
threshold (VT) idea of Price et al.,9 which uses the
maximum of the test statistics over all allele-frequency
thresholds and assesses statistical significance by permuta-
tion. The forgoing methods assume that the effects of the
combined rare mutations on the phenotype are in the
same direction. To detect opposite effects, Han and Pan101Department of Biostatistics, University of North Carolina, Chapel Hill, NC 2
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burden test, whereas Neale et al.11 and Wu et al.12 tested
the variance of the effects.
In this article, we provide a general framework for associ-
ation testingwith rare variants that reflects the spirits of the
existing methods but is statistically more powerful and
computationally more efficient. Our framework covers all
major study designs (i.e., case-control, cross-sectional,
cohort and family studies) and all common phenotypes
(e.g., binary and quantitative traits, and potentially cen-
sored ages at onset of disease) and allows any covariates
(e.g., environmental factors and ancestry variables). The
ability to accommodate covariates is critically important
because population stratification is expected to be a more
severe issue with rare variants than with common variants
but could be corrected by including suitable ancestry vari-
ables (e.g., the percentage of African ancestry or principal
components for ancestry) in the association analysis. We
combine information across multiple variant sites within
a gene by taking a weighted sum of the mutation counts
for each study subject and relate the combined information
and covariates to disease phenotypes through appropriate
regressionmodels. We derive theoretically optimal weights
that would produce the most powerful tests among all
valid tests and develop the corresponding testing proce-
dures. We employ score-type statistics, which are numeri-
cally stable even in the case of extremely rare variants and
computationally fast even in the presence of covariates.
We provide asymptotic normal approximation for both
fixed-threshold and VTmethods and develop permutation
and other resampling tests that can accommodate
covariates. We investigate theoretically and numerically
when normal approximation is appropriate and when7599, USA
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resampling is required. We modify the popular methods of
Madsen and Browning8 and Price et al.9 to enhance statis-
tical power, avoid permutation, and accommodate covari-
ates. We construct data-adaptive test statistics that are
powerful even when the combined rare mutations have
opposite effects on the phenotype. The advantages of the
proposedmethods over the existing ones are demonstrated
both analytically and empirically. The software imple-
menting the proposed methods is available at our website.Material and Methods
Suppose that a total of n subjects are genotyped on a total of m
SNPs in a gene and that there are d covariates. Here, the word
‘‘gene’’ refers to the group of variants that will be collectively
analyzed and might pertain to a subset of SNPs within a gene or
to a region or pathway involving multiple genes; covariates might
include nongenetic variables, such as age and smoking status, as
well as ancestry variables, such as the percentage of African
ancestry and principal components for ancestry. For i ¼ 1;.;n,
let Yi be the phenotype value of the ith subject; for i ¼ 1;.;n
and j ¼ 1;.;m, let Xji denote the number of the rare mutation
the ith subject carries at the jth SNP; for i ¼ 1;.;n and
j ¼ 1;.; d, let Zji denote the value of the jth covariate on the ith
subject. We can define
Xi ¼
24 X1i«
Xmi
35; Zi ¼
2664
1
Z1i
«
Zdi
3775:
We focus on binary phenotypes in the main text but consider all
common phenotypes in Appendix A. It is natural to relate Yi to Xi
and Zi through the logistic regression model:
Pr ðYi ¼ 1Þ ¼ e
bTXiþgTZi
1þ e bTXiþgTZi ; (Equation 1)
where b and g arem3 1 and (dþ 1)31 vectors of unknown regres-
sion coefficients. Because the first component of Zi is 1, the first
component of g corresponds to the intercept. We can write
b ¼ tx, where t is a scalar constant, and x ¼ b=t. Then Equation
(1) becomes
Pr ðYi ¼ 1Þ ¼ e
tSiþgTZi
1þ e tSiþgTZi ; (Equation 2)
where Si ¼ xTXi. Note that x ¼ ðx1;.; xmÞT is a m 3 1 vector of
weights and that Si is a weighted linear combination of
X1i;.;Xmi with Xji receiving the weight xj. We will refer to x as
the weight function.
The score statistic for testing the null hypothesisH0 : t ¼ 0 takes
the form
U ¼
Xn
i¼1
 
Yi  e
bgTZi
1þ ebgTZi
!
Si;
where bg is the restricted maximum likelihood estimator of g and
solves the equation
Xn
i¼1
 
Yi  e
gTZi
1þ egTZi
!
Zi ¼ 0:The AmericanThe variance of U is estimated by
V ¼
Xn
i¼1
viS
2
i 
 Xn
i¼1
viSiZi
!T Xn
i¼1
viZiZ
T
i
!1 Xn
i¼1
viSiZi
!
;
where
vi ¼ e
bgTZi
1þ ebgTZi2:
Under H0, the test statistic T ¼ U=V1=2 is asymptotically standard
normal. In the absence of covariates,
U ¼
Xn
i¼1
ðYi  YÞSi;
and
V ¼ Yð1 YÞ
(Xn
i¼1
S2i  n1
 Xn
i¼1
Si
!2)
;
where Y ¼ n1Pni¼1Yi.
The true value of the weight function x ¼ ðx1;.; xmÞT is
unknown and must be determined biologically or empirically. If
we set xj ¼ 1ðj ¼ 1;.;mÞ, then T is a burden test, which counts
the total number of rare mutations each subject carries over the
m SNPs. If we believe that common variants are not associated
with the phenotype, then we set xj ¼ 0 if pj > c, where pj is the
minor allele frequency (MAF) of the jth SNP, and c is a given
threshold. If we set xj ¼ fpjð1 pjÞg1=2ðj ¼ 1;.;mÞ, then the
weight function is in the same vein as that of Madsen and
Browning.8
If the choice of the weight function x is not proportional to b or
x is estimated from the data, then U is no longer the score statistic.
However, we show in Appendix A that the test statistic T is asymp-
totically standard normal under H0 regardless of how x is deter-
mined. The only condition is that if x is estimated from the data,
then the estimate converges to a constant vector as the sample
size n increases. This condition is satisfied by all sensible estimates,
including those based on estimated allele frequencies. If the
choice of x or the limit of the estimate of x is proportional to b,
then the corresponding test statistic T is themost powerful among
all valid tests.
The weight function x is similar to that of Price et al.9 The latter
authors showed that, for case-control studies with known allele
frequencies in the control population, the choice of xj ¼
fpjð1 pjÞg1=2ðj ¼ 1;.;mÞ corresponds to the implicit assump-
tion that logðORjÞffpjð1 pjÞg1=2ðj ¼ 1;.;mÞ, where ORj is the
odds ratio in the 2 3 2 table for the jth SNP. Our theory is much
more general in that it assumes unknown allele frequencies and
accommodates covariates. Indeed, the proposed test statistic is
optimal if x is proportional to the set of regression coefficients
(in the limit); this result holds for all phenotypes, including binary
and continuous traits, as well as potentially censored ages at onset
of disease.
Madsen and Browning8 suggested to set xj ¼ fbpjð1 bpjÞg1=2
ðj ¼ 1;.;mÞ, where bpj is the estimate of the MAF of the jth SNP
in the unaffected subjects. Because the weights depend on the
phenotype values, the authors suggested a permutation-based
test. Our testing framework allows such data-dependent weights
because the frequency estimates converge to the true values as n
increases. To improve the accuracy of asymptotic approximation,
we suggest estimating the frequencies from all study subjectsJournal of Human Genetics 89, 354–367, September 9, 2011 355
rather than the unaffected subjects. Because the variants can be
very rare, we recommend adding pseudocounts when estimating
the frequencies, as was done by Madsen and Browning.8 The
weight functions based on the frequency estimates in the pooled
sample and the unaffected subjects will be denoted by Fp and Fu,
respectively; the constant weight function will be denoted by C.
The corresponding tests will be referred to as the Fp test, the Fu
test and the C test.
Although Fu is the weight function used by Madsen and Brown-
ing,8 our Fu test is fundamentally different from the Madsen and
Browning (MB) test. The latter is based on the sum of the ranks
of the Si’s with weight function Fu over the affected subjects. Mad-
sen and Browning8 proposed to assess the statistical significance of
their rank-sum statistic by permutation. They also suggested an
asymptotic normal approximation by standardizing the rank-
sum statistic by its mean and standard derivation. Because the
mean and standard derivation are estimated by permutation, the
asymptotic version of the MB test is many orders of magnitudes
slower than our asymptotic tests. The rank-sum statistic is
confined to case-control analysis without covariates.
Price et al.9 developed a VT method by taking the maximum of
the test statistics (i.e., Z scores) over all allele-frequency thresholds
and assessing statistical significance by permutation. We describe
below a more general approach that allows not only multiple
allele-frequency thresholds but also different types of weight
function; it also accommodates covariates and does not require
permutation.
We consider K choices of x, which could correspond to different
thresholds or different types of weight function, or both. (It is
assumed that K is small relative to n.) For the kth choice of x, the
corresponding Si is denoted by Ski. Then the score statistic is
Uk ¼
Xn
i¼1
 
Yi  e
bgTZi
1þ ebgTZi
!
Ski;
and the test statistic is Tk ¼ Uk=V1=2k , where
Vk ¼
Xn
i¼1
viS
2
ki 
 Xn
i¼1
viSkiZi
!T Xn
i¼1
viZiZ
T
i
!1 Xn
i¼1
viSkiZi
!
:
It is shown in Appendix A that, under H0, the random vector
ðU1;.;UKÞT is approximately K-variate normal with mean 0 and
covariance matrix fVkl; k; l ¼ 1;.;Kg, where
Vkl ¼
Xn
i¼1
UkiUli;
and
Uki ¼
 
Yi  e
bgTZi
1þ ebgTZi
!(
Ski 
 Xn
i¼1
viSkiZi
!T Xn
i¼1
viZiZ
T
i
!1
Zi
)
:
For the two-sided test, we consider the maximum of the absolute
test statistics
Tmax ¼ max
k¼1;.;K
jTkj :
Let tmax be the observed value of Tmax. The p value is given by
Pr ðTmaxRtmaxÞ ¼ 1 Pr ð jT1j < tmax;.; jTKj < tmaxÞ;
which is evaluated by treating ðT1;.;TKÞT as a K-variate normal
random vector with a mean of 0 and a covariance matrix of
frkl; k; l ¼ 1;.;Kg, where rkl ¼ Vkl=ðVkkVllÞ1=2. (The one-sided356 The American Journal of Human Genetics 89, 354–367, Septembp value can be calculated in a similar manner.) We reject H0 if
the p value is smaller than the nominal significance level a.
The tests based on positive weight functions, such as C, Fu, and
Fp, will have low power if the mutations being combined have
opposite effects on the phenotype. The optimal choice of xj is bj,
which is unknown. We can estimate bj from the data. It would
be tempting to set xj to bbj, where bbj is an appropriate estimate of
bj. There are two major problems with this strategy. First, the test
statistic T will not be asymptotically normal. Second, the bbj’s are
highly variable (because the individual variants are very rare)
and can be quite different from the true values of the bj’s. As
a compromise, we set xj ¼ bbj þ d, where d is a given constant. We
refer to this weight function as EREC, an abbreviation of estimated
regression coefficients. The corresponding test statistic T will be
asymptotically standard normal as long as d is nonzero. Indeed,
the EREC test is asymptotically optimal in that xj will converge
to bj if we let d decrease to 0 as the sample size n increases to N.
The asymptotic normality and optimality require very large
samples. For small samples, we recommend to use a relatively large
value of d so that the weights are not unduly driven by the highly
variable bbj’s. For n < 2000, we set d ¼ 1 for binary traits and d ¼ 2
for standardized quantitative traits.
The sequence kernel association test (SKAT) of Wu et al.12
assumes that bj follows an arbitrary distribution with a mean of
0 and a variance of xjn, and tests the null hypothesis that n ¼ 0
by using a variance-component score statistic. The SKAT statistic
can be written as Q ¼Pmj¼1xjU2j , where Uj is the jth component
of the score statistic for testing the null hypothesis that b ¼ 0
under Equation 1. The C-alpha statistic of Neale et al.11 is a special
case of Qwith xj ¼ 1 for binary traits without covariates. Our score
statistic U can be written as
Pm
j¼1xjUj. The Han and Pan
10 (HP)
statistic is a special case of U (for binary traits without covariates)
in which xj ¼ 1 if bbj < 0 and the corresponding p value<0.1 and
in which xj ¼ 1 otherwise.
Because the asymptotic approximationmight not be accurate in
small samples, especially when the weight function x involves the
phenotype values Yi’s, we also provide permutation-type tests. In
the absence of covariates, we simply permute the phenotype
values Yi’s and calculate the test statistic T for each permutation.
Note that it is necessary to recalculate the Si’s after permuting
the Yi’s if the weight function x depends on the Yi’s.
Our permutation differs from that of Price et al.9 in that we
permute T, whereas they permuted
Pn
i¼1YiSi. The former is a
pivotal statistic, whereas the latter is not. (It is desirable to permute
a pivotal statistic.13) If the test is one-sided and the weight func-
tion does not depend on the phenotype values, then our permuta-
tion is equivalent to Price et al.’s9; otherwise, the two are different.
For VT methods, the numerators in the Z scores of Price et al.9 are
the same as ours, but the denominators are not the same as or
proportional to ours. Thus, the permutation p values are generally
different between the two methods. The permutation version of
the MB test requires ranking the Si’s for each permutation and is
thus substantially slower than our permutation tests.
In the presence of covariates, permuting the Yi’s it is not appro-
priate because Yi is generally correlated with Zi. Instead, we
generate Yi from the fitted null model:
Pr

Yi ¼ 1
 ¼ ebgTZi
1þ ebgTZi ;
replace the Yi’s with the Y

i ’s, and recalculate the test statistic. (The
recalculation of the test statistic starts with re-estimating g ander 9, 2011
Table 1. Type I Errora and Power of Asymptotic Methods with Different Weight Functions
n a
H0 : bj ¼ 0 H1 : bj ¼ x bj ¼ x/{pj(1  pj)}1/2
C Fp Tmax Fu C Fp Tmax Fu C Fp Tmax Fu
500 102 0.95 0.95 0.93 2.12 0.76 0.73 0.75 0.86 0.75 0.77 0.77 0.89
103 0.82 0.79 0.78 2.51 0.49 0.44 0.47 0.64 0.47 0.49 0.48 0.68
104 0.68 0.63 0.60 2.52 0.25 0.21 0.23 0.39 0.23 0.25 0.24 0.42
1000 102 0.98 0.97 0.97 1.96 0.81 0.77 0.80 0.88 0.89 0.91 0.90 0.96
103 0.92 0.89 0.89 2.53 0.55 0.50 0.54 0.67 0.68 0.73 0.71 0.84
104 0.88 0.74 0.78 3.05 0.31 0.27 0.30 0.43 0.44 0.49 0.47 0.65
2000 102 0.98 0.98 0.98 1.64 0.92 0.90 0.92 0.95 0.95 0.97 0.96 0.98
103 0.96 0.95 0.95 2.04 0.76 0.71 0.75 0.81 0.82 0.86 0.85 0.92
104 0.91 0.88 0.88 2.44 0.54 0.47 0.52 0.61 0.62 0.68 0.67 0.79
4000 102 1.00 0.99 0.99 1.37 0.97 0.96 0.97 0.98 0.97 0.98 0.97 0.99
103 0.98 0.98 0.97 1.61 0.88 0.84 0.87 0.90 0.86 0.90 0.89 0.94
104 0.98 0.96 0.94 1.85 0.72 0.65 0.70 0.74 0.69 0.75 0.73 0.82
a Divided by a.recalculating the Si’s.) This process is repeated and is called (para-
metric) bootstrap.13 Both permutation and bootstrap are resam-
pling methods. In the absence of covariates, PrðYi ¼ 1Þ is the
sample proportion of cases.
Obtaining an accurate estimate of a small p value requires a large
number of resamples (i.e., permutations or bootstrap samples).
However, most p values are relatively large and can be estimated
accurately with a small number of resamples. Thus, we employ
a multistage procedure which filters out large p values with small
numbers of resamples and uses large numbers of resamples only
for the most extreme p values.Results
Simulation Studies
We conducted extensive simulation studies to investigate
the performance of the proposed and existing methods.
We simulated case-control data with an equal number of
cases and controls from Equation 1 in which the first
component of g was set to –2. We considered mainly
the following six combinations of MAFs: (1) pj ¼ 0:001j
ðj ¼ 1;.;10Þ with a total frequency of 5.5%; (2)
pj ¼ 0:0005j ðj ¼ 1;.; 10Þ with a total frequency of
2.75%; (3) pj ¼ 0:00025j ðj ¼ 1;.;20Þ with a total
frequency of 5.25%; (4) pj ¼ 0:005 ðj ¼ 1;.; 10Þ with a
total frequency of 5%; (5) pj ¼ 0:0025 ðj ¼ 1;.;10Þ with a
total frequency of 2.5%; and (6) pj ¼ 0:0025 ðj ¼ 1;.;20Þ
with a total frequency of 5%. The genotype values were
simulated under Hardy-Weinberg equilibrium and linkage
equilibrium. We did not use sophisticated population
genetics models because we wished to control the number
of variants and their frequencies, which allowed us to see
clearly how the proposed and existing methods perform
under various scenarios. We evaluated both asymptoticThe Americanand resampling methods. When the simulation studies
involved asymptotic methods only, we used 10 millions
replicates (i.e., simulated data sets) to evaluate type I error
and 100,000 replicates to evaluate power at a ¼ 102;
103, and 104. When the simulation studies involved
resampling methods, we used 1 million replicates to eval-
uate type I error and 10,000 replicates to evaluate power
at a ¼ 102 and 103. The resampling p values were ob-
tained from a three-stage procedure with a maximum of
1 million resamples. The null hypothesis corresponded
to H0 : bj ¼ 0 ðj ¼ 1;.;mÞ. We considered alternative hy-
potheses such as H1 : bj ¼ x ðj ¼ 1;.;mÞ and H1 : bj ¼ x=
fpjð1 pjÞg1=2 ðj ¼ 1;.;mÞ, where x was chosen such that
the power (of the most powerful method) was reasonably
high at a ¼ 102. We report below results from six series
of simulation studies, the first four without covariates
and the last two with covariates. The tests were two-sided
except for the third series.
We designed our first series of simulation studies to eval-
uate the proposed asymptotic methods with different
weight functions. We considered the aforementioned six
combinations of MAFs and generated data under the null
hypothesis H0 : bj ¼ 0 ðj ¼ 1;.;mÞ, as well as two alterna-
tive hypotheses H1 : bj ¼ x ðj ¼ 1;.;mÞ and H1 : bj ¼
x=fpjð1 pjÞg1=2ðj ¼ 1;.;mÞ.Weconsidered three (positive)
weight functions: C, Fp, and Fu. We also considered the
maximum of the test statistics based on weight functions C
and Fp, which will be referred to as Tmax. The results for the
first combination of MAFs are displayed in Table 1, whereas
those of the remaining five combinations are provided in
Tables S1–S5, available online. The performance of the tests
is affected more by the total allele frequency than the
number of variants or individual MAFs. The C test, Fp test,
and Tmax are conservative but less so as n, a, or total alleleJournal of Human Genetics 89, 354–367, September 9, 2011 357
Table 2. Type I Errora and Power of Asymptotic and Permutation
Methods
n a
Asymptotic Permutation
C Fp MB C Fp Fu Price
b MB
H0 : bj ¼ 0
500 102 0.99 0.98 0.98 0.71 1.02 1.02 1.01 1.00
103 0.89 0.87 0.89 0.62 0.99 1.01 0.99 1.01
1000 102 1.00 1.00 1.00 0.79 1.01 1.03 1.01 1.01
103 0.96 0.96 0.93 0.72 1.01 1.02 1.01 1.02
H1 : bj ¼ x
500 102 0.84 0.81 0.82 0.81 0.81 0.81 0.79 0.82
103 0.57 0.54 0.54 0.54 0.55 0.54 0.49 0.56
1000 102 0.86 0.84 0.85 0.85 0.84 0.84 0.82 0.85
103 0.63 0.58 0.60 0.60 0.59 0.58 0.53 0.60
H1 : bj ¼ x/{pj(1  pj)}1/2
500 102 0.83 0.85 0.82 0.80 0.85 0.84 0.81 0.82
103 0.56 0.59 0.54 0.52 0.59 0.57 0.51 0.55
1000 102 0.93 0.95 0.92 0.92 0.95 0.94 0.93 0.92
103 0.75 0.80 0.73 0.73 0.80 0.77 0.74 0.74
a Divided by a.
b With weight function Fu.
Table 3. Type I Errora and Power of Fixed-Threshold and VT
Methods
n a
Asymptotic Permutation
T1 T5 VT T1 T5 VT Priceb
H0 : bj ¼ 0
500 102 0.91 0.96 0.84 0.62 0.72 0.90 0.88
103 0.79 0.85 0.57 0.54 0.61 0.83 0.83
1000 102 0.96 0.99 0.86 0.73 0.81 0.93 0.93
103 0.88 0.90 0.66 0.68 0.70 0.89 0.88
H1 : b1 ¼. ¼ b10 ¼ x, b11 ¼ 0
500 102 0.39 0.59 0.66 0.34 0.55 0.67 0.67
103 0.15 0.29 0.36 0.13 0.27 0.40 0.39
1000 102 0.50 0.61 0.68 0.46 0.58 0.69 0.69
103 0.23 0.33 0.40 0.21 0.30 0.43 0.43
H1 : b1 ¼. ¼ b11 ¼ x
500 102 0.29 0.82 0.71 0.25 0.80 0.72 0.71
103 0.10 0.57 0.42 0.09 0.54 0.46 0.45
1000 102 0.35 0.82 0.68 0.32 0.81 0.69 0.68
103 0.13 0.57 0.41 0.12 0.54 0.44 0.42
a Divided by a.
b VT method of Price et al.9frequency increases. As expected, theC test ismore powerful
than the Fp test under the first alternativehypothesis and less
powerful under the second alternative hypothesis; Tmax is
nearly as powerful as the C test under the first alternative
and nearly as powerful as the Fp test under the second
alternative. The Fu test is unacceptably liberal; therefore, we
will not consider this asymptotic test any further.
Our second series of studies was devoted to comparisons
of asymptotic and permutation methods. In addition to
the proposed methods, we evaluated the asymptotic and
permutation versions of the MB test, as well as the permu-
tation method of Price et al.9 with weight function Fu. We
simulated data in the same manner as the first series of
studies. We performed one-sided tests because the MB
and Price et al. tests were designed as one-sided. The results
for the first combination of MAFs are displayed in Table 2.
Because of the discreteness of the test statistic, the permu-
tation version of the C test is more conservative than its
asymptotic counterpart and consequently less powerful.
The permutation Fp and Fu tests do not appear to be conser-
vative; the former appears to be slightly more powerful
than the latter. The MB test was designed for the second
alternative hypothesis, for which the proposed asymptotic
test based on weight function Fp is more powerful than the
asymptotic version of the MB test whereas the proposed
permutation tests based on weight functions Fp and Fu
are more powerful than the permutation version of the
MB test. For weight function Fu, our permutation test is
more powerful than that of Price et al.9358 The American Journal of Human Genetics 89, 354–367, SeptembIn the third series of studies, we compared fixed-
threshold and VT methods. We simulated 11 SNPs with
MAFs pj ¼ 0:001j ðj ¼ 1;.;10Þ and p11 ¼ 0:03. We consid-
ered the null hypothesis H0 : b1 ¼ b2 ¼. ¼ b11 ¼ 0, as
well as two alternative hypotheses H1 : b1 ¼ b2 ¼. ¼
b10 ¼ x, b11 ¼ 0 and H1 : b1 ¼ b2 ¼. ¼ b11 ¼ x. For
fixed-threshold methods, we considered the thresholds of
0.01 and 0.05; the corresponding tests are referred to as
the T1 and T5 tests. For VT methods, we excluded the
thresholds for which the total numbers of rare mutations
were fewer than 10. As shown in Table 3, all the tests
appear to be conservative, especially when n and a are
small. The permutation T1 and T5 tests are more conserva-
tive than their asymptotic counterparts. In theory, T1 and
T5 are the most powerful under the first and second alter-
natives, respectively. Because the frequency estimates for
rare variants are highly variable, T1 turns out to be the least
powerful among all the tests under the first alternative. The
VT tests have good power under both alternatives, and the
asymptotic and permutation versions have similar power.
The permutation version of our VT test is slightly more
powerful than that of Price et al.9
In the fourth set of studies, we compared the C test, Fp
test, and EREC test, as well as the HP, C-alpha, and SKAT
tests. Note that the last four tests were designed to detect
variants with opposite effects. The EREC, HP, and C-alpha
tests were based on permutation, whereas the SKAT was
based on the Davies method.12 For the EREC test, bbj was
the estimate of the log odds ratio bj (after addinger 9, 2011
Table 4. Type I Errora and Power of Asymptotic and Permutation
Tests for Detecting Potentially Opposite Effects
n a
Asymptotic Permutation
C Fp SKAT C Fp EREC HP C-alpha
H0 : bj ¼ 0
500 102 0.95 0.95 0.53 0.68 1.00 1.01 0.89 0.91
103 0.83 0.77 0.26 0.60 0.94 0.97 0.91 0.87
1000 102 0.99 0.98 0.75 0.77 1.02 1.02 0.97 0.96
103 0.97 0.95 0.57 0.73 1.02 1.04 1.01 0.97
H0 : bj ¼ x
500 102 0.77 0.74 0.33 0.73 0.74 0.72 0.71 0.36
103 0.49 0.45 0.09 0.46 0.47 0.44 0.41 0.14
1000 102 0.81 0.77 0.41 0.78 0.77 0.78 0.73 0.42
103 0.56 0.50 0.16 0.53 0.51 0.51 0.42 0.17
H1 : bj ¼ x/{pj(1  pj)}1/2
500 102 0.76 0.78 0.26 0.73 0.79 0.71 0.70 0.27
103 0.47 0.50 0.06 0.44 0.51 0.41 0.39 0.08
1000 102 0.66 0.70 0.22 0.63 0.70 0.65 0.57 0.21
103 0.37 0.41 0.06 0.35 0.42 0.35 0.26 0.06
H1 : b1 ¼ . ¼ b8 ¼ x, b9 ¼ x, b10 ¼  2x
500 102 0.29 0.23 0.58 0.25 0.23 0.76 0.63 0.61
103 0.09 0.06 0.25 0.08 0.06 0.49 0.38 0.32
1000 102 0.31 0.27 0.81 0.28 0.27 0.88 0.86 0.81
103 0.10 0.08 0.54 0.09 0.09 0.66 0.65 0.56
H1 : b1 ¼ . ¼ b9 ¼ x, b10 ¼ x / 2
500 102 0.77 0.74 0.50 0.74 0.75 0.82 0.76 0.54
103 0.49 0.45 0.21 0.46 0.47 0.57 0.47 0.26
1000 102 0.86 0.85 0.69 0.84 0.85 0.92 0.86 0.70
103 0.64 0.61 0.40 0.61 0.62 0.73 0.60 0.42
H1 : b2 ¼ b4 ¼ b6 ¼ b8 ¼ x, b10 ¼ x, bj ¼ 0 (j ¼ 1, 3, 5, 7, 9 )
500 102 0.19 0.13 0.41 0.16 0.14 0.56 0.34 0.47
103 0.05 0.03 0.14 0.05 0.03 0.26 0.13 0.21
1000 102 0.24 0.17 0.65 0.21 0.17 0.71 0.54 0.67
103 0.07 0.04 0.35 0.06 0.05 0.42 0.27 0.39
H1 : b3 ¼ 2x, b4 ¼ 2x, b5 ¼ x, b6 ¼ x, b j ¼ 0 (j ¼ 1, 2, 7 ~ 10)
500 102 0.10 0.02 0.61 0.08 0.02 0.69 0.18 0.65
103 0.01 0.00 0.27 0.01 0.00 0.36 0.06 0.36
1000 102 0.12 0.03 0.88 0.11 0.03 0.90 0.43 0.86
103 0.03 0.00 0.63 0.02 0.00 0.66 0.21 0.62
a Divided by a.
Table 5. Type I Errora and Power of Fixed-Threshold and VT
Methods with Covariates
n a
Asymptotic Bootstrap
T1 T5 Fp VT T1 T5 Fp VT
H0 : bj ¼ 0
500 102 0.97 1.00 0.98 0.90 1.01 1.02 1.01 1.01
103 0.82 0.99 0.92 0.75 0.94 1.00 0.98 0.97
1000 102 0.97 0.99 0.99 0.88 0.99 1.00 1.00 0.98
103 0.90 0.98 0.94 0.79 0.94 0.98 0.96 0.94
H1 : b1 ¼. ¼ b10 ¼ x, b11 ¼ 0
500 102 0.23 0.46 0.56 0.53 0.23 0.46 0.57 0.55
103 0.06 0.19 0.27 0.25 0.07 0.19 0.27 0.27
1000 102 0.31 0.50 0.62 0.58 0.31 0.50 0.62 0.59
103 0.11 0.23 0.33 0.30 0.11 0.23 0.33 0.32
H1 : b1 ¼. ¼ b11 ¼ x
500 102 0.19 0.79 0.77 0.72 0.19 0.79 0.77 0.73
103 0.04 0.54 0.48 0.44 0.05 0.54 0.49 0.45
1000 102 0.26 0.89 0.82 0.77 0.27 0.89 0.82 0.78
103 0.08 0.68 0.56 0.51 0.08 0.68 0.56 0.53
a Divided by a.a pseudocount of 1 to each of the four cells in the
232 table). For the SKAT test, we used the default weighted
linear kernel function. We set pj ¼ 0:001j ðj ¼ 1;.;10Þ and
considered the null hypothesis H0 : bj ¼ 0 ðj ¼ 1;.; 10ÞThe Americanand six alternative hypotheses representing different
numbers of causal variants anddifferent patternsofpositive
andnegative effects. As shown inTable 4, the SKAT is highly
conservative, especially when n and a are small. The EREC
test is slightly less powerful than the C test and Fp test
when the SNP effects are all positive but is much more
powerful than the latter when there are opposite effects.
The EREC test is more powerful than the HP test. It is also
more powerful than the C-alpha and SKAT, especially
when the mean of the regression coefficients is not 0.
The above four sets of studies contained no covariates.
We also conducted extensive studies with covariates. We
generated data in the same manner as before except that
we added a normally distributed covariate whose mean is
equal to the total number of rare mutations and whose
variance is equal to 1 and we set its regression coefficient
to 0.3. Some key results are presented in Tables 5 and 6.
The T1, T5, Fp, and VT tests are less conservative than in
the case of no covariates, and their asymptotic and boot-
strap versions have similar power. The EREC test has
similar power to the C and Fp tests when all SNP effects
are positive and is much more powerful than the latter
when there are opposite effects. The EREC test tends to
be more powerful than the SKAT, especially when the
mean of the regression coefficients is not 0.Real Data
We considered high-depth sequence data from the exons
of 202 genes encoding known or potential drug targets14
for 1957 subjects randomly drawn from the CoLausJournal of Human Genetics 89, 354–367, September 9, 2011 359
Table 6. Type I Errora and Power of Asymptotic and Bootstrap
Tests for Detecting Potentially Opposite Effects in the Presence of
Covariates
n a
Asymptotic Bootstrap
C Fp SKAT C Fp EREC
H0 : bj ¼ 0
500 102 0.97 0.97 0.63 1.00 1.00 0.97
103 0.85 0.80 0.37 0.94 0.92 0.93
1000 102 0.98 0.97 0.81 0.99 0.99 0.98
103 1.01 0.96 0.56 1.05 1.01 0.99
H1 : bj ¼ x
500 102 0.67 0.63 0.14 0.67 0.63 0.67
103 0.37 0.33 0.02 0.37 0.33 0.37
1000 102 0.74 0.69 0.23 0.74 0.70 0.75
103 0.45 0.40 0.06 0.46 0.41 0.47
H1 : bj ¼ x/{pj(1  pj)}1/2
500 102 0.65 0.68 0.32 0.65 0.68 0.65
103 0.35 0.37 0.08 0.36 0.38 0.35
1000 102 0.58 0.63 0.47 0.59 0.63 0.62
103 0.30 0.33 0.18 0.30 0.33 0.32
H1 : b1 ¼ . ¼ b8 ¼ x, b9 ¼ x, b10 ¼  2x
500 102 0.20 0.14 0.55 0.20 0.14 0.73
103 0.05 0.03 0.23 0.06 0.03 0.44
1000 102 0.22 0.18 0.81 0.22 0.18 0.84
103 0.06 0.04 0.55 0.07 0.04 0.61
H1 : b1 ¼ . ¼ b9 ¼ x, b10 ¼ x / 2
500 102 0.67 0.63 0.31 0.67 0.63 0.78
103 0.36 0.32 0.09 0.37 0.33 0.50
1000 102 0.79 0.76 0.53 0.79 0.77 0.89
103 0.51 0.48 0.23 0.52 0.49 0.67
H1 : b2 ¼ b4 ¼ b6 ¼ b8 ¼ x, b10 ¼ x, bj ¼ 0 (j ¼ 1, 3, 5, 7, 9 )
500 102 0.13 0.08 0.34 0.13 0.08 0.48
103 0.03 0.01 0.11 0.03 0.01 0.21
1000 102 0.17 0.12 0.61 0.17 0.12 0.64
103 0.05 0.03 0.31 0.05 0.03 0.35
H1 : b3 ¼ 2x, b4 ¼ 2x, b5 ¼ x, b6 ¼ x, b j ¼ 0 (j ¼ 1, 2, 7 ~ 10)
500 102 0.04 0.02 0.47 0.04 0.02 0.53
103 0.01 0.00 0.14 0.01 0.00 0.23
1000 102 0.07 0.01 0.82 0.07 0.01 0.81
103 0.01 0.00 0.52 0.01 0.00 0.52
a Divided by a.population-based collection.15 We analyzed total choles-
terol (available in 1899 subjects) as a quantitative trait
and included eight covariates in the analysis: gender, age,360 The American Journal of Human Genetics 89, 354–367, Septembage2, and the top five principal components for ancestry
constructed from the GWAS SNP data. One subject without
the gender and age information was removed. We em-
ployed the methods for quantitative traits described in
Appendix A.
We restricted our analysis to polymorphic variants that
are nonsense, missense, or splice site mutations. We
removed variants with observed MAFs>5% or mis-
singness>10%.We excluded any gene whose total number
of rare mutations is less than five and ended up with a total
of 172 genes. There were a total of 2304 variants in these
172 genes, and the number of variants per gene varied
from 1 to 70, with a median of 11. We applied both the
asymptotic and permutation versions of our T1, T5, Fp,
and VT tests, as well as the permutation EREC test. We
calculated the two-sided p values. With 172 genes, the
Bonferroni threshold at the 0.05 significance level corre-
sponds to a p value of 0.0003 or –log10(p value) of 3.5.
The results based on the asymptotic and permutation
methods are shown in Figures 1 and 2, respectively. One
gene was identified as the most significant by all the tests:
the asymptotic p values for T1, T5, Fp, and VT are 0.00011,
0.00011, 0.00021, and 0.00057, respectively; the corre-
sponding permutation p values are 0.00013, 0.00013,
0.00025, and 0.0012, respectively; the p value of the EREC
test is 0.00012. (The name of the gene is not disclosed
here because the main study has not been published yet.)
All the p values, except the VT’s, pass the Bonferroni crite-
rion. Similar evidence of association has been observed in
other samples of the sequencing project.14 There were 13
variants in the top gene. Their observed MAFs ranged
from 0.00026 to 0.0024, the total frequency being 1.13%.
Because the observed MAFs are all less than 1% in this
case, T1 and T5 are the same test. For the VT test, the
maximum occurs at the highest MAF. It is interesting to
point out that common SNPs in the top gene were previ-
ously identified to be associated with total cholesterol.16
We also performed a binary trait analysis by comparing
high (i.e.,>6.2mmol/l) anddesirable (i.e.,<5.2mmol/l) total
cholesterol values. There were 451 subjects with high total
cholesterol and 683 subjects with desirable total cholesterol.
The results of the analysis are shown in Figures 3 and 4. All
the tests identified the same top gene as was identified
in the quantitative trait analysis: the asymptotic p values
for T1, T5, Fp, and VT are 0.00022, 0.00022, 0.00057, and
0.00088, respectively; the corresponding bootstrap p values
are 0.00019, 0.00019, 0.00039, and 0.00033, respectively.
Again, T1 and T5 are the same test. The maximum of the
VT test occurs at the highest MAF, at which threshold 18
out of the 451 subjects with high cholesterol values carry
the rare mutations as opposed to 7 out of 683 subjects with
desirable cholesterol values. The p value of the bootstrap
EREC test is 0.000021, which is the most extreme among
all the tests and is even more extreme than all the p values
of the quantitative trait analysis. For eight out of the 10 vari-
ants in the top gene, there were moremutations in the high
group than in the desirable group (17 versus two); for theer 9, 2011
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Figure 1. Quantile-Quantile Plots of p Values on the –log10 Scale for the Asymptotic T1, T5, Fp, and VT Tests in the Quantitative Trait
Analysis of Total Cholesterolremaining two variants, there were fewer mutations in the
high group than in the desirable group (one versus five).
Thus, allowing opposite effects yielded stronger evidence
of association than assuming effects of the same direction.
Finally, we compared the proposed methods to the exist-
ing ones. The results for the SKAT are shown in Figure S1
(top panel). For the top gene, the SKAT yielded the p values
of 0.0014 and 0.00024 in the quantitative and binary trait
analyses, respectively, which are 10 times larger than the
p values of our EREC test. Because the other existing
methods do not allow covariates and some of them require
binary traits, we also performed the binary trait analysis
without the covariates for all the methods. The resultsThe Americanare shown in the bottom panel of Figure S1 and in Figures
S2–S4. Although the top gene remains the same, the results
without covariate adjustment (for the top gene) are con-
siderably less significant than those with covariate adjust-
ment. For the top gene, the EREC test yielded a much
more significant result (p value ¼0.00013) than all the
other tests.Discussion
We developed a very general framework for the association
analysis of rare variants. This framework enabled us toJournal of Human Genetics 89, 354–367, September 9, 2011 361
0 1 2 3 4
0
1
2
3
4
Expected
O
bs
er
ve
d
EREC
0 1 2 3 4
0
1
2
3
4
Expected
O
bs
er
ve
d
T5
0 1 2 3 4
0
1
2
3
4
Expected
O
bs
er
ve
d
Fp
0 1 2 3 4
0
1
2
3
4
Expected
O
bs
er
ve
d
VT
Figure 2. Quantile-Quantile Plots of p Values on the –log10 Scale for the Permutation EREC, T5, Fp, and VT Tests in the Quantitative
Trait Analysis of Total Cholesterolevaluate existing methods and develop other methods.
Our theoretical analysis and simulation studies yielded
insights into the behavior of the existing methods. The
normal approximation works very well for the proposed
methods, and resampling is required only when the weight
function depends on the phenotype values. The proposed
methods are numerically stable and easy to implement.
The asymptotic tests are extremely fast. A computer
program implementing the proposed methods is posted
at our website. For a typical exome-sequencing study, it
takes only a few hours to run all the proposed asymptotic
and resampling tests.362 The American Journal of Human Genetics 89, 354–367, SeptembWe have adopted score-type statistics, which are
computationally faster and more stable than Wald and
likelihood ratio (LR) statistics because the null model
does not involve rare variants and needs to be fit only
once. Our simulation studies revealed that Wald tests
tend to be overly conservative (resulting in substantial
loss of power) whereas likelihood ratio tests tend to
be too liberal (resulting in excessive false-positive find-
ings), especially for small n and low MAFs; see Tables
S6–S8.
Our work improves upon the pioneer work of Madsen
and Browning8 by using more powerful test statistics,er 9, 2011
0 1 2 3 4
0
1
2
3
4
Expected
O
bs
er
ve
d
T1
0 1 2 3 4
0
1
2
3
4
Expected
O
bs
er
ve
d
T5
0 1 2 3 4
0
1
2
3
4
Expected
O
bs
er
ve
d
Fp
0 1 2 3 4
0
1
2
3
4
Expected
O
bs
er
ve
d
VT
Figure 3. Quantile-Quantile Plots of p Values on the –log10 Scale for the Asymptotic T1, T5, Fp, and VT Tests in the Binary Trait
Analysis of Total Cholesterolaccommodating covariates and avoiding permutation. For
case-control studies, Madsen and Browning8 estimated the
allele frequencies in the unaffected subjects only so that
a true signal from an excess of mutations in the affected
subjects would not be deflated by using the total number
of mutations in both affected and unaffected subjects.
According to our theory, the allele frequencies in the
unaffected subjects will be optimal if logðORjÞf
fpjð1 pjÞg1=2ðj ¼ 1;.;mÞ and pj is the frequency of the
jth variant in the unaffected subjects. Even if that is the
truth, the frequency estimates are highly variable and
can be very different from the true values. The frequency
estimates in the pooled sample of affected and unaffectedThe Americansubjects are more stable and the corresponding Fp test
can be implemented through normal approximation
(rather than resampling).
The optimal choice of the frequency threshold depends
on the nature of association, which is generally unknown.
In addition, the frequency estimates for rare variants are
highly variable, especially for small samples with substan-
tial missing data. Thus, VT methods might be preferable to
fixed-threshold methods. Our VTapproach improves upon
that of Price et al.9 in three aspects: (1) it uses more power-
ful test statistics, (2) it can accommodate covariates, (3) it
can be implemented by normal approximation instead of
permutation.Journal of Human Genetics 89, 354–367, September 9, 2011 363
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Figure 4. Quantile-Quantile Plots of p Values on the –log10 Scale for the Bootstrap EREC, T5, Fp, and VT Tests in the Binary Trait
Analysis of Total CholesterolThe EREC test is capable of detecting rare mutations
with opposite effects. Simulation studies (Tables 4 and 6)
showed that the EREC test has similar power to the tests
assuming the same direction of effects when that assump-
tion holds and is much more powerful than the latter
when that assumption fails. In addition, the EREC test
outperforms the HP, C-alpha and SKAT tests. In the real
data example, the EREC test produced themost convincing
evidence of association for the top gene among all the tests.
Thus, we recommend the EREC test for general use.
The SKAT is computationally faster than the EREC, HP,
and C-alpha tests because it calculates p values analytically.
Simulation studies revealed that the SKAT is overly conser-364 The American Journal of Human Genetics 89, 354–367, Septembvative, especially when n and a are small. The resampling
methods developed in this article can be used to obtain
accurate p values for the SKAT, and indeed any other tests,
with or without covariates.
Statistical analysis of rare variants is a very active research
area. Several othermethodshavebeenpublishedduring the
preparation of this article.17–19 We have not compared our
methods to all existing methods for several reasons: (1) we
wished to focus on the most commonly used current
methods, (2) some of the newly published methods are
based on different philosophies and thus would be difficult
to compare directly, (3) a comprehensive comparison of all
existing methods is beyond the scope of this article.er 9, 2011
It is possible to incorporate biological and computa-
tional information about the functional effects of rare
variants, such as SIFT20 and PolyPhen21 scores, into the
association analysis. Indeed, our theory allows incorpora-
tion of any prior knowledge into the weight function. Effi-
cient use of functional or bioinformatics information
requires further investigation. It would be worthwhile to
explore Bayesian methods.
Grouping methods for rare variants are in the same vein
as the SNP-set methods for GWAS studies22–24 in that
multiple SNPs within a group are analyzed collectively to
enhance statistical power. Because the data are extremely
sparse for individual rare variants, the SNP-set methods
for common variants might not be applicable to rare vari-
ants. On the other hand, the methods for rare variants can
potentially be used to combine low-frequency SNPs in
GWAS studies.
We have considered one group of variants at a time. It
might be desirable to analyze several groups of variants
simultaneously. Our approach can be readily extended to
multiple groups of variants. Specifically, we divide variants
into, say, K groups according to certain criteria (e.g., MAFs)
and combine the information within each group. We can
express the score statistic for each group of variants as a
sum of n efficient score functions (see Appendix A) so
that the asymptotic joint distribution of the K score statis-
tics follows from the multivariate central limit theorem.
We can then use the asymptotic joint distribution to
form a multivariate test statistic. If we choose the
maximum of the K test statistics, then the formulas for K
weight functions presented in Material and Methods can
be directly applied. If we choose the chi-square statistic
with K degrees of freedom, then our method would be a
generalization of the combined multivariate and
collapsing (CMC) method of Li and Leal.7
We used the Bonferroni correction in the analysis of
the real data. This criterion is conservative if there is strong
linkage disequilibrium (LD) among the genes. More accu-
rate correction for multiple testing can be achieved by
accounting for the correlations of the test statistics. There
are two possible ways to do so: one is to use permutation
and the other is to use Monte Carlo.25 The latter is based
on efficient score functions, which are provided in
Appendix A.
This work and indeed all existing literature assume that
the quantitative trait data are obtained from a random
sample. In many sequencing studies, including several in
the National Heart, Lung, and Blood Institute (NHLBI)
Exome Sequencing Project that we are involved with,
only the subjects with the extreme values of a quantitative
trait are selected for sequencing. The case-control testing is a
validoptionbutmightbe inefficient if there is aquantitative
association. In addition, it might be desirable to analyze
quantitative traits that are not the one used to select the
subjects for sequencing. We are currently developing valid
and efficient methods for the association analysis of quan-
titative traits under such trait-dependent sampling.The AmericanAppendix A
We relate Yi toXi and Zi through a generalized linear model
with the linear predictor bTXi þ gTZi, where b ¼ tx. Let h
consist of g and other nuisance parameters. Let lðt; h; xÞ
denote the log-likelihood function for t and h with a fixed
value of x. The corresponding score function and observed
Fisher information matrix are

Utðt; h; xÞ
Uhðt; h; xÞ

;
and 
Ittðt; h; xÞ Ithðt; h; xÞ
Ihtðt; h; xÞ Ihhðt; h; xÞ

;
where Utðt; h; xÞ ¼ vlðt; h; xÞ=vt,Uhðt; h; xÞ ¼ vlðt; h; xÞ=vh,
Ittðt; h; xÞ¼v2lðt; h; xÞ=vt2, Ithðt; h; xÞ¼ v2lðt; h; xÞ=vtvhT,
Ihtðt; h; xÞ ¼ ITthðt; h; xÞ, and Ihhðt; h; xÞ ¼ v2lðt; h; xÞ=vhvhT.
The score statistic for testing the null hypothesis
H0 : t ¼ 0 is Utð0; bh; xÞ, where bh is the solution to the
equation Uhð0; h; xÞ ¼ 0. Under H0, the random variable
n1=2Utð0; bh; xÞ is asymptotically zero-mean normal with
a variance that can be consistently estimated by26
n1
n
Itt

0; bh; x Ith0; bh; xI1hh 0; bh; xIht0; bh; xo:
Suppose that x is estimated from the data by bx. Then we
replace x in Utð0; bh; xÞ by bx. It can be shown that
Utð0; h; xÞ ¼ xTUbð0; hÞ, where Ubðb; hÞ is the score function
of b under Equation 1. Because n1=2Ubð0; bhÞ is asymptoti-
cally zero-mean normal, bxT n1=2Ubð0; bhÞhas the same
asymptotic distribution as xTn1=2Ubð0; bhÞ, where x is
the limit of bx. As a result, n1=2Utð0; bh; bxÞhas the same
asymptotic distribution as n1=2Utð0; bh; xÞ. Thus, the test
statistic
Ut

0; bh; bxn
Itt

0; bh; bx Ith0; bh; bxI1hh 0; bh; bxIht0; bh; bxo1=2
is asymptotically standard normal as long as bx converges to
a nonzero constant as n/N.
Let Ut;iðt; h; xÞ and Uh;iðt; h; xÞ be the ith subject’s contri-
butions to Utðt; h; xÞ and Uhðt; h; xÞ, respectively, and let Sth
and Shh be the limits of n
1Ithð0; h; xÞ and n1Ihhð0; h; xÞ,
respectively. It is easy to show that n1=2Utð0; bh; xÞ is
asymptotically equivalent to n1=2
Pn
i¼1ui, where
ui ¼ Ut;ið0; h; xÞ  SthS1hh Uh;ið0; h; xÞ:
We refer to ui as the ith subject’s efficient score function.
27
To derive the joint distribution of the test statistics with K
weight functions, we use the fact that n1=2Uk
is asymptotically equivalent to n1=2
Pn
i¼1uki, where uki is
the ith subject’s efficient score function associated with
the kth weight function. Note that ðu1i;.; uKiÞði ¼
1;.; nÞ are n independent random vectors. By theJournal of Human Genetics 89, 354–367, September 9, 2011 365
multivariate central limit theorem and law of large
numbers, the null distribution of n1=2ðU1;.;UKÞ is
asymptotically zero-mean normal, and the covariance
between n1=2Uk and n1=2Ul is consistently estimated by
n1
Pn
i¼1UkiUli, where the Uki’s are obtained from the uki’s
by replacing all unknown parameters by their sample esti-
mators.
For quantitative traits, we replace Equation 2 with the
linear regression model:
Yi ¼ tSi þ gTZi þ ei;
where εi is normal with mean 0 and variance s
2. Then the
score statistic and its variance are
U ¼
Xn
i¼1

Yi  bgTZiSi;
and
V ¼ bs2(Xn
i¼1
S2i 
 Xn
i¼1
SiZi
!T Xn
i¼1
ZiZ
T
i
!1 Xn
i¼1
SiZi
!)
;
where
bg ¼  Xn
i¼1
ZiZ
T
i
!1Xn
i¼1
YiZi;
and
bs2 ¼ n1Xn
i¼1

Yi  bgTZi2:
For multiple weight functions,
Uk ¼
Xn
i¼1

Yi  bgTZiSki;
and
Uki ¼

Yi  bgTZi
(
Ski 
 Xn
i¼1
SkiZi
!T Xn
i¼1
ZiZ
T
i
!1
Zi
)
:
To perform permutation tests without covariates, we
simply permute the Yi’s. In the presence of covariates, we
adopt the following procedure: (1) calculate the residuals
Ri ¼ Yi  bgTZiði ¼ 1;.;nÞ, (2) permute the Ri’s to yield the
Ri ’s, (3) create new trait values Y

i ¼ bgTZi þ Ri ði ¼ 1;.; nÞ,
(4) replace the Yi’s by the Y

i ’s, (5) recalculate the test
statistic, and (6) repeat steps 2–5 a large number of times.
We have implicitly assumed that the trait is univariate
and the subjects are unrelated. For repeated measures or
family studies, we use generalized linear mixed models28
to capture the dependence of trait values. Suppose that
the study contains n families with ni members in the ith
family. For i ¼ 1;.;n and l ¼ 1;.;ni, let Yil, Sil and Zil
denote the values of Y, S, and Z for the lth member of
the ith family. The random effects bi ði ¼ 1;.; nÞ are inde-
pendent zero-mean random vectors with density function366 The American Journal of Human Genetics 89, 354–367, Septembf ðb; qÞ indexed by a set of parameters q. Conditional on bi,
the trait values Yi1;.;Yi;ni are independent and follow
a generalized linear model with density f ðyj Sil; Zil; biÞ.
The log-likelihood function is
lðt; h; xÞ ¼
Xn
i¼1
log
Z
b
Yni
l¼1
f ðYil j Sil; Zil; bÞf ðb; qÞdb;
where t is the fixed effect of Sil, and h includes the fixed
effects of Zil and parameters q. For repeated measures, the
log-likelihood takes the same form with Yil and Zil being
the trait and covariate values at the lth measurement
time for the ith subject and with Sil replaced by Si. We
can then use the arguments of the first three paragraphs
to derive the test statistics.
For potentially censored age-at-onset traits, we specify
that the hazard function for the age at onset conditional
on Si and Zi satisfies the proportional hazards model
29
lðt j Si; ZiÞ ¼ l0ðtÞetSiþgTZi ;
where l0 is an arbitrary baseline hazard function and Zi is
redefined to exclude the unit component. Let Ti denote
the duration of follow-up for the ith subject, and let Di
indicate, by the values 1 versus 0, whether Ti is the actual
age at onset or the censoring time. Then the score statistic
and its variance are
U ¼
Xn
i¼1
Di
0BB@Si 
P
j˛Ri
ebgTZjSjP
j˛Ri
ebgTZj
1CCA;
and V ¼ Itt  ItgI1gg Igt, whereRi denotes the set of subjects
whose durations of follow-up are no shorter than Ti, bg is
the solution to the equation
Xn
i¼1
Di
0B@Zi 
P
j˛Ri
eg
TZjZjP
j˛Ri
eg
TZj
1CA ¼ 0;

Itt Itg
Igt Igg

¼
Xn
i¼1
DiP
j˛Ri
ebgTZj
(X
j˛Ri
ebgTZj Sj
Zj
52

 X
j˛Ri
ebgTZj!1 X
j˛Ri
ebgTZj Sj
Zj
!52)
;
and a52 ¼ aaT. For multiple weight functions, we obtain
the efficient score functions by approximating the partial
likelihood score function with a sum of n independent
terms.30Supplemental Data
Supplemental Data include four figures and eight tables and can be
found with this article online at http://www.ajhg.org.er 9, 2011
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